Want to see LXEO full AI Analyst Report?
Top Page
Lexeo Therapeutics, Inc.
(NASDAQ:LXEO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.00
▼(-41.52% Downside)
Action:Reiterated
Date:10/02/26
The score is held down mainly by weak financial performance (zero revenue with significant ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting factors include a comparatively low-debt balance sheet and positive pipeline-related corporate events (RMAT status, pivotal trial progress, and an FA pipeline expansion), while valuation metrics are limited by negative earnings and no dividend support.
Positive Factors
Low Leverage
Very low leverage limits financial risk from borrowing and preserves flexibility to fund clinical development. Positive equity also provides a stronger base for pursuing programs and milestones, although it does not eliminate the need for future financing while the company remains pre-commercial.
Negative Factors
No Commercial Revenue
The absence of recurring product revenue means Lexeo has not yet demonstrated commercial traction or an operating engine that can fund development. Progress therefore remains dependent on clinical success and eventual commercialization, leaving the business model economically unproven over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits financial risk from borrowing and preserves flexibility to fund clinical development. Positive equity also provides a stronger base for pursuing programs and milestones, although it does not eliminate the need for future financing while the company remains pre-commercial.
Read all positive factors
Lexeo Therapeutics, Inc. (LXEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$246.26M
Dividend YieldN/A
Average Volume (3M)1.77M
Price to Earnings (P/E)―
Beta (1Y)2.42
Revenue GrowthN/A
EPS Growth64.51%
CountryUS
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding82,088,160
10 Day Avg. Volume1,623,030
30 Day Avg. Volume1,774,090
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.16
Price to Sales (P/S)0.00
P/FCF Ratio-5.38
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-354.76
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$18.00Price Target Upside250.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.22
Revenue Forecast (FY)N/A
Lexeo Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX...
How the Company Makes Money
As a clinical-stage biotechnology company, Lexeo Therapeutics does not have publicly available information indicating it generates recurring revenue from marketed products; accordingly, ongoing operations are primarily funded through external fina...
Lexeo Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| Gross Profit | -546.00K | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| EBITDA | -84.96M | -97.68M | -96.19M | -64.35M | -58.04M | -50.61M |
| Net Income | -87.27M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
Balance Sheet | ||||||
| Total Assets | 254.90M | 268.69M | 146.94M | 139.81M | 97.08M | 136.86M |
| Cash, Cash Equivalents and Short-Term Investments | 211.70M | 181.77M | 121.52M | 121.47M | 77.33M | 135.86M |
| Total Debt | 6.81M | 7.89M | 9.92M | 11.64M | 13.48M | 0.00 |
| Total Liabilities | 19.84M | 22.02M | 30.10M | 26.27M | 210.03M | 192.46M |
| Stockholders Equity | 235.06M | 246.67M | 116.84M | 113.53M | -112.95M | -55.60M |
Cash Flow | ||||||
| Free Cash Flow | -88.70M | -98.96M | -81.63M | -59.66M | -55.46M | -44.37M |
| Operating Cash Flow | -88.37M | -98.56M | -81.15M | -59.50M | -54.56M | -44.18M |
| Investing Cash Flow | -24.95M | -90.25M | -94.08M | -165.00K | -901.00K | -188.00K |
| Financing Cash Flow | 170.68M | 216.79M | 88.78M | 103.79M | 189.00K | 150.86M |
Lexeo Therapeutics, Inc. Technical Analysis
Negative
5.13
Price Trends
4.00
Negative
4.31
Negative
5.39
Negative
Market Momentum
-0.32
Negative
37.02
Neutral
55.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXEO, the sentiment is Negative. The current price of 5.13 is above the 20-day moving average (MA) of 3.12, above the 50-day MA of 4.00, and below the 200-day MA of 5.39, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 37.02 is Neutral, neither overbought nor oversold. The STOCH value of 55.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LXEO.
Lexeo Therapeutics, Inc. Risk Analysis
Lexeo Therapeutics, Inc. disclosed 75 risk factors in its most recent earnings report. Lexeo Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lexeo Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $467.54M | -12.07 | -77.68% | ― | ― | -3.42% | |
48 Neutral | $246.26M | -2.61 | -41.85% | ― | ― | 64.51% | |
46 Neutral | $315.34M | -8.67 | -28.41% | 0.12% | ― | 14.04% | |
45 Neutral | $13.61M | -0.37 | -145.40% | ― | -100.00% | 82.57% | |
45 Neutral | $384.30M | -2.40 | -56.60% | ― | -100.00% | -49.28% | |
44 Neutral | $253.47M | -1.22 | -137.39% | ― | ― | -27.00% |
* Healthcare Sector Average
LXEO
Lexeo Therapeutics, Inc.
2.89
-6.11
-67.89%
TVRD
Tvardi Therapeutics
0.97
-4.19
-81.16%
LRMR
Larimar Therapeutics
2.27
-1.68
-42.53%
CAPR
Capricor Therapeutics
6.13
0.00
0.00%
BNTC
Benitec Biopharma
8.82
-6.99
-44.21%
DMAC
Diamedica Therapeutics
8.63
1.87
27.66%
Lexeo Therapeutics, Inc. Corporate Events
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Lexeo Therapeutics Reports Unregistered Equity Issuances Post-Merger
Neutral
Sep 29, 2026
Lexeo Therapeutics disclosed that it issued shares of its common stock in connection with a merger transaction, relying on exemptions from registration under the Securities Act of 1933 and applicable state securities laws, including Section 4(a)(2...
Business Operations and StrategyM&A Transactions
Lexeo Therapeutics expands FA pipeline with Mantle acquisition
Positive
Sep 22, 2026
On September 16, 2026, Lexeo Therapeutics agreed to acquire private clinical-stage FA specialist Mantle Therapeutics for $8.3 million in cash and stock, plus up to $13 million in contingent milestone payments, adding multiple oral, protein replace...
Business Operations and StrategyFinancial Disclosures
Lexeo Therapeutics advances gene therapy and gains RMAT status
Positive
Aug 12, 2026
On August 12, 2026, Lexeo Therapeutics reported second-quarter 2026 results and detailed progress across its gene therapy portfolio, underscoring a push toward pivotal development in inherited heart diseases. In June, the company finalized the SUN...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.